Xtant Medical GAAP EPS of $0.02 beats by $0.03, revenue of $35.4M beats by $4.05M

* Xtant Medical press release [https://seekingalpha.com/pr/20197138-xtant-medical-reports-second-quarter-2025-financial-results] (NYSE:XTNT [https://seekingalpha.com/symbol/XTNT]): Q2 GAAP EPS of $0.02 beats by $0.03.
* Revenue of $35.4M beats by $4.05M.
* Gross margin of 68.6% compared to 62.1% for the prior year quarter
* Net income of $3.6 million compared to a net loss of $3.9 million in the prior year quarter
* Adjusted EBITDA of $6.9 million compared to Adjusted EBITDA loss of $0.6 million in the prior year quarter
* Cash generated from operations of $1.2 million compared to cash used in operations of $5.1 million in the prior year quarter
* Raised FY25 revenue guidance to $131-$135 million, representing growth of 11%-15%, excluding the impact of the pending sale of certain assets to Companion Spine
*

MORE ON XTANT MEDICAL

* Xtant Medical beats top-line and bottom-line estimates; raises FY25 outlook [https://seekingalpha.com/news/4483783-xtant-medical-beats-top-line-and-bottom-line-estimates-raises-fy25-outlook]
* Seeking Alpha’s Quant Rating on Xtant Medical [https://seekingalpha.com/symbol/XTNT/ratings/quant-ratings]
* Historical earnings data for Xtant Medical [https://seekingalpha.com/symbol/XTNT/earnings]
* Financial information for Xtant Medical [https://seekingalpha.com/symbol/XTNT/income-statement]